clinical trial · NCT03715933
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Ewing SarcomaINBRX-109IrinotecanTemozolomidecarboplatinpemetrexedLeucovorinFluorouracil
brief summary
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
started
Oct 8, 2018
primary completion
Jun 1, 2026
completion
Dec 1, 2026
last updated
Mar 18, 2026
official title
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol